Subtype
Hepatopancreatobiliary Carcinoma
CI-CAN-00002859Explore in graph →
1,360 active trials21 approved drugs69 evidence items
- NCIt
- C214986
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002859Explore in graph →
Clinical trials
5,150 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (645)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07827807 | PEARL Trial: Partial TACE Enhancing Anti-tumor Response With Lenvatinib in Unresectable HCC(Pearl) | not yet recruiting | Phase 2 | 40 | Chang Gung Memorial HospitalOTHER | 0 | Sep 18, 2026 | clinicaltrials |
| NCT07828236 | PHASE 1 TRIAL OF Lm-LLO-TT AND GEMCITABINE IN UNRESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA | not yet recruiting | Phase 1 | 18 | Loki Therapeutics, Inc.INDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07829185 | Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer(FALCON) | not yet recruiting | Phase 1 | 30 | University of OklahomaOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT02851784 | Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma | recruiting | Phase 2 / Phase 3 | 80 | Chinese PLA General HospitalOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06275737 | POP-UP: a Single-arm, Two-cohort Study: an 8-week Trimodal Pre-habilitation Program for Patients With Pancreatic Ductal Adenocarcinoma and Oesogastric(POP-UP) | recruiting | N/A | 72 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07027436 | Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.(DARTS) | recruiting | Phase 3 | 30 | Hamilton Health Sciences CorporationOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07349537 | Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors | recruiting | Phase 1 | 574 | Revolution Medicines, Inc.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07824583 | A Study Evaluating a New Radiation Treatment Workflow (NGDS)(SPEED) | recruiting | N/A | 20 | Varian, a Siemens Healthineers CompanyINDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07824765 | Heterogeneity of Treatment Effects of Adding Locoregional Therapies to Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma (ISMIO-026) | not yet recruiting | — | 2,658 | Zhongda HospitalOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07824960 | Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma(Panc 004) | not yet recruiting | Phase 1 / Phase 2 | 31 | University of VirginiaOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07825519 | Effectiveness of Enhanced Web-Based Health Education on Self-Care Practices and Quality of Life Among Patients With Hepatocellular Carcinoma Undergoing TACE | active not recruiting | N/A | 252 | University Medical Center Ho Chi Minh City (UMC)OTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07826780 | The STRONG Nutrition Support Study for People With Pancreatic Cancer(STRONG) | not yet recruiting | N/A | 80 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT03028311 | Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer | active not recruiting | Phase 1 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT03460080 | Diagnostic Value of AFP-L3 and PIVKA-II in HCC | completed | — | 200 | Hanoi Medical UniversityOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06252545 | Promoting CT Engagement for Pancreatic Cancer With App(PROCLAIM) | recruiting | N/A | 26 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06427941 | A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 630 | BeOne MedicinesINDUSTRY | 9 | Sep 16, 2026 | clinicaltrials |
| NCT06574620 | Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment(ACCELERATE) | recruiting | N/A | 200 | British Columbia Cancer AgencyOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07823348 | JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer | not yet recruiting | Phase 3 | 560 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT02381561 | Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy | active not recruiting | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05692596 | The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics | active not recruiting | — | 317 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05908786 | A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 62 | Hoffmann-La RocheINDUSTRY | 6 | Sep 15, 2026 | clinicaltrials |
| NCT06007846 | A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer | recruiting | Phase 2 / Phase 3 | 12 | Inova Health Care ServicesOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06263088 | EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer. | recruiting | N/A | 200 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06412510 | Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT | active not recruiting | Phase 1 / Phase 2 | 1 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06968195 | Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma | suspended | Phase 1 | 24 | Roswell Park Cancer InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07255001 | Using Strength Tests to Better Understand How Pancreatic Cancer Affects Muscle Mass and Quality of Life(PanFit) | recruiting | N/A | 50 | British Columbia Cancer AgencyOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07341737 | SL-28 for Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 60 | Second Life TherapeuticsINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07540832 | A Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC | not yet recruiting | Phase 1 / Phase 2 | 80 | Zhejiang Haichang Biotech Co., Ltd.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07702292 | [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | recruiting | Phase 2 | 71 | Blue Earth DiagnosticsINDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT07776080 | Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus | recruiting | Phase 2 | 35 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT01300143 | Association of Conformational High-dose Radiotherapy and of Hyperselective Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma(TACERTE) | completed | Phase 2 | 126 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03533582 | Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery | active not recruiting | Phase 3 | 537 | Children's Oncology GroupNETWORK | 6 | Sep 14, 2026 | clinicaltrials |
| NCT04111172 | A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma | suspended | Phase 2 | 48 | Thomas Jefferson UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04140526 | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC(PRESERVE-001) | active not recruiting | Phase 1 / Phase 2 | 733 | OncoC4, Inc.INDUSTRY | 2 | Sep 14, 2026 | clinicaltrials |
| NCT04380545 | Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer | recruiting | Phase 1 / Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04708067 | Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma | active not recruiting | Phase 1 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04721132 | Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer | active not recruiting | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04858009 | Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis | recruiting | Phase 2 | 40 | Mayo ClinicOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05059444 | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation(ORACLE) | recruiting | — | 2,285 | Guardant Health, Inc.INDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT05482516 | Evaluating Novel Therapies in ctDNA Positive GI Cancers(MRD-GI) | recruiting | Phase 3 | 20 | Georgetown UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05799274 | Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors(RAD301) | active not recruiting | Phase 1 | 9 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05858736 | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors(PRESERVE-009) | completed | Phase 1 | 18 | OncoC4, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05883644 | Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)(SIERRA) | active not recruiting | Phase 3 | 111 | AstraZenecaINDUSTRY | 10 | Sep 14, 2026 | clinicaltrials |
| NCT06789198 | Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion DNAJB1-PRKACA(FusionVAC22_02) | recruiting | Phase 1 | 20 | University Hospital TuebingenOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07365839 | Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma(CLeAR) | withdrawn | Phase 1 | 0 | Virginia Commonwealth UniversityOTHER | 0 | Sep 14, 2026 | clinicaltrials |
| NCT07491445 | Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma(RASolute 303) | recruiting | Phase 3 | 900 | Revolution Medicines, Inc.INDUSTRY | 10 | Sep 14, 2026 | clinicaltrials |
| NCT01585805 | Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | active not recruiting | Phase 2 | 83 | National Cancer Institute (NCI)NIH | 3 | Sep 11, 2026 | clinicaltrials |
| NCT02772003 | DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection | active not recruiting | Phase 1 | 33 | National Cancer Institute (NCI)NIH | 2 | Sep 11, 2026 | clinicaltrials |
| NCT03878550 | Case-Control Study of the Glycotest™ HCC Panel vs AFP for the Detection of Early-stage Hepatocellular Carcinoma | active not recruiting | — | 766 | Glycotest, Inc.INDUSTRY | 2 | Sep 11, 2026 | clinicaltrials |
| NCT04665947 | First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer | active not recruiting | Early Phase 1 | 30 | University of California, DavisOTHER | 1 | Sep 11, 2026 | clinicaltrials |
Data updated 12 days agoSource updated Sep 18, 2026source: clinicaltrials